Should vascular effects of newer treatments be addressed more completely?

Eric H. Yang; Karol E. Watson; Joerg Herrmann

doi:10.2217/fon.15.119

Should vascular effects of newer treatments be addressed more completely?

Eric H. Yang, Karol E. Watson, Joerg Herrmann

Cardiovascular Medicine

Research output: Contribution to journal › Review article › peer-review

9 Scopus citations

Original language	English (US)
Pages (from-to)	1995-1998
Number of pages	4
Journal	Future Oncology
Volume	11
Issue number	14
DOIs	https://doi.org/10.2217/fon.15.119
State	Published - Jul 1 2015

Keywords

cardio-oncology
cardiotoxicity
dasatinib
imatinib resistance
leukemia
nilotinib
peripheral arterial disease
ponatinib
tyrosine kinase inhibitors
vascular toxicity

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.2217/fon.15.119

Cite this

@article{e7a0f6458e9346dca34ef9caf0665146,

title = "Should vascular effects of newer treatments be addressed more completely?",

keywords = "cardio-oncology, cardiotoxicity, dasatinib, imatinib resistance, leukemia, nilotinib, peripheral arterial disease, ponatinib, tyrosine kinase inhibitors, vascular toxicity",

author = "Yang, {Eric H.} and Watson, {Karol E.} and Joerg Herrmann",

year = "2015",

month = jul,

day = "1",

doi = "10.2217/fon.15.119",

language = "English (US)",

volume = "11",

pages = "1995--1998",

journal = "Future Oncology",

issn = "1479-6694",